ProQR Therapeutics N.V. Enters Underwriting Agreement
Ticker: PRQR · Form: 6-K · Filed: Oct 25, 2024 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $3.50, $59.0 m, $12.3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: underwriting-agreement, capital-raise, foreign-private-issuer
TL;DR
ProQR inked an underwriting deal on Oct 22, 2024. Capital raise incoming?
AI Summary
On October 22, 2024, ProQR Therapeutics N.V. entered into an underwriting agreement. This filing is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Why It Matters
This agreement likely relates to the company's efforts to raise capital, which could impact its ability to fund ongoing research and development or future operations.
Risk Assessment
Risk Level: medium — Underwriting agreements can signal a need for capital, which may dilute existing shareholders or indicate financial pressures.
Key Players & Entities
- ProQR Therapeutics N.V. (company) — Filer and party to the underwriting agreement
- October 22, 2024 (date) — Date of the underwriting agreement
FAQ
What is the purpose of the underwriting agreement entered into by ProQR Therapeutics N.V. on October 22, 2024?
The provided text states that ProQR Therapeutics N.V. entered into an underwriting agreement on October 22, 2024, but does not specify its purpose.
What is the filing type and date for ProQR Therapeutics N.V.'s submission?
The filing type is a Form 6-K, and it was filed as of October 25, 2024.
What is ProQR Therapeutics N.V.'s principal executive office address and phone number?
The principal executive offices are located at Zernikedreef 9, 2333 CK Leiden, The Netherlands, and the phone number is +31 88 166 7000.
Does ProQR Therapeutics N.V. file annual reports under Form 20-F or Form 40-F?
ProQR Therapeutics N.V. indicates it files annual reports under cover of Form 20-F.
What is the Central Index Key (CIK) for ProQR Therapeutics N.V.?
The Central Index Key for ProQR Therapeutics N.V. is 0001612940.
Filing Stats: 1,412 words · 6 min read · ~5 pages · Grade level 12.7 · Accepted 2024-10-25 16:07:27
Key Financial Figures
- $3.50 — g price of the Shares to the public was $3.50 per share (the "Public Offering Price")
- $59.0 m — ds from the Offering were approximately $59.0 million, after deducting the underwriting
- $12.3 million — gregate purchase price of approximately $12.3 million (the "Private Placement"). The closing
Filing Documents
- tm2426654d4_6k.htm (6-K) — 24KB
- tm2426654d4_ex1-1.htm (EX-1.1) — 232KB
- tm2426654d4_ex5-1.htm (EX-5.1) — 41KB
- tm2426654d4_ex10-1.htm (EX-10.1) — 210KB
- tm2426654d4_ex99-1.htm (EX-99.1) — 11KB
- tm2426654d4_ex99-2.htm (EX-99.2) — 14KB
- 0001104659-24-111473.txt ( ) — 533KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROQR THERAPEUTICS N.V. Date: October 25, 2024 By: /s/ René Beukema René Beukema Chief Corporate Development Officer and General Counsel INDEX TO EXHIBITS Number Description 1.1 Underwriting Agreement, dated October 22, 2024, between the Company and Evercore Group L.L.C. and Cantor Fitzgerald & Co. 5.1 Opinion of Allen Overy Shearman Sterling LLP. 10.1 Share Purchase Agreement, dated October 22, 2024, between the Company and Eli Lilly and Company. 23.1 Consent of Allen & Overy LLP (included in Exhibit 5.1). 99.1 Press Release of ProQR Therapeutics N.V. dated October 22, 2024. 99.2 Press Release of ProQR Therapeutics N.V. dated October 23, 2024.